Adamas Pharma (ADMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 74,461 | 54,637 | 34,046 | 571 | 572 |
| Cost of Goods | 2,038 | 2,469 | 633 | 17 | 0 |
| Gross Profit | 72,423 | 52,168 | 33,413 | 554 | 572 |
| Operating Expenses | 116,625 | 144,872 | 149,068 | 88,497 | 61,556 |
| Operating Income | -44,164 | -92,235 | -115,022 | -87,926 | -60,984 |
| Interest Expense | 13,987 | 15,044 | 19,092 | 4,645 | 0 |
| Other Income | 748 | 2,093 | 3,115 | 1,351 | 811 |
| Pre-tax Income | -57,403 | -105,186 | -130,999 | -91,220 | -60,173 |
| Income Tax | N/A | N/A | N/A | -1,730 | -115 |
| Net Income Continuous | -57,403 | -105,186 | -130,999 | -89,490 | -60,058 |
| Net Income | $-57,403 | $-105,186 | $-130,999 | $-89,490 | $-60,058 |
| EPS Basic Total Ops | -2.03 | -3.80 | -4.87 | -3.97 | -2.77 |
| EPS Basic Continuous Ops | -2.03 | -3.80 | -4.87 | -3.97 | -2.77 |
| EPS Diluted Total Ops | -2.03 | -3.80 | -4.87 | -3.97 | -2.77 |
| EPS Diluted Continuous Ops | -2.03 | -3.80 | -4.87 | -3.97 | -2.77 |
| EPS Diluted Before Non-Recurring Items | -2.03 | -3.80 | -4.87 | -3.97 | -2.77 |
| EBITDA(a) | $-43,448 | $-92,240 | $-114,607 | $-86,276 | $-60,477 |